Yohei Yamamoto

ORCID: 0000-0001-9838-3211
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Aortic aneurysm repair treatments
  • Vascular Procedures and Complications
  • Bone Metabolism and Diseases
  • Bone health and treatments
  • Peripheral Artery Disease Management
  • Cancer, Hypoxia, and Metabolism
  • Vascular Malformations Diagnosis and Treatment
  • Foot and Ankle Surgery
  • Angiogenesis and VEGF in Cancer
  • Cancer Immunotherapy and Biomarkers
  • Tendon Structure and Treatment
  • Immunotherapy and Immune Responses
  • Infectious Aortic and Vascular Conditions
  • Lower Extremity Biomechanics and Pathologies
  • Osteoarthritis Treatment and Mechanisms
  • Aortic Disease and Treatment Approaches
  • Immune cells in cancer
  • Diabetic Foot Ulcer Assessment and Management
  • Knee injuries and reconstruction techniques
  • Sports injuries and prevention
  • Central Venous Catheters and Hemodialysis
  • Cancer Research and Treatments
  • Abdominal vascular conditions and treatments
  • Cytokine Signaling Pathways and Interactions

Tokyo Medical and Dental University
2016-2024

The Jikei University Hospital
2020-2024

Jikei University School of Medicine
2015-2024

Hirosaki University
2019-2024

Tokushima University
2021-2023

Chiba University
2014-2023

Fukushima Medical University
2023

Kyoto Prefectural University of Medicine
2023

Niigata University
2023

Kanazawa Medical University
2023

Osteoclasts are multinucleated cells that resorb bone. Although osteoclasts originate from the monocyte/macrophage lineage, osteoclast precursors not well characterized in vivo. The relationship between proliferation and differentiation of is examined this study using murine macrophage cultures treated with colony-stimulating factor (M-CSF) receptor activator NF-κB (RANK) ligand (RANKL). Cell cycle–arrested quiescent (QuOPs) were identified as committed vitro. In vivo experiments show QuOPs...

10.1083/jcb.200806139 article EN cc-by-nc-sa The Journal of Cell Biology 2009-02-23

Background: An intra-articular injection of platelet-rich plasma (PRP) may be an effective treatment for osteoarthritis (OA). However, its efficacy in ankle OA has not been investigated yet. The purpose this study was to assess the safety and PRP patients with during a 24-week period. Methods: Twenty ankles 20 varus-type who received injections were evaluated. extracted from whole blood by using double-spin technique. Three 2-mL administered at interval 2 weeks under ultrasonographic...

10.1177/1071100717700377 article EN Foot & Ankle International 2017-04-11

Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors initial resection (naïve Bev group), resected following therapy (effective and recurrent after (refractory group). paired samples post-Bev from 9 patients were included. expression programmed cell death-1 (PD-1)/PD ligand-1...

10.1111/cas.13889 article EN cc-by-nc-nd Cancer Science 2018-11-23

The interaction between high-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) is important tumor cell growth. We investigated the biological effects of HMGB1 RAGE interaction. Previously, we identified an inhibitor HMGB1/RAGE interaction, papaverine (a non-narcotic opium alkaloid), using a unique drug design system repositioning approach. In present study, examined anticancer in human glioblastoma (GBM) temozolomide (TMZ; as first-line...

10.1371/journal.pone.0216358 article EN cc-by PLoS ONE 2019-05-17

Abstract Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in under and after therapy, including angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), placental (PLGF), fibroblast 2, ephrin A2 (EphA2). Fifty-four GBM tissues, 28 specimens from 14 cases as paired the same patient obtained three settings: initial tumor resection...

10.1007/s10014-024-00481-0 article EN cc-by Brain Tumor Pathology 2024-04-01

Prostaglandin E(2) (PGE(2)) enhances osteoclast formation in mouse macrophage cultures treated with receptor activator of nuclear factor-kappaB ligand (RANKL). The effects PGE(2) on human were examined CD14(+) cells prepared from peripheral blood mononuclear cells. differentiated into osteoclasts the presence RANKL and colony-stimulating factor. expressed EP2 EP4, but not EP1 or EP3, whereas cell-derived none receptors. PGE(1) alcohol (an EP2/4 agonist) stimulated cAMP production In contrast...

10.1210/en.2005-0451 article EN Endocrinology 2005-09-09

The purposes of this study were to clarify the incidence anxiety and depression among patients with chronic foot ankle diseases examine independent association pain quality life.Patients who visited clinic from April 2015 November 2016 recruited. Anxiety in assessed using Hospital Depression Scale. Pain life evaluated visual analog scale (VAS) Self-Administered Foot Evaluation Questionnaire (SAFE-Q), respectively. Furthermore, patient characteristics, including age, sex, body mass index,...

10.1177/1071100717723133 article EN Foot & Ankle International 2017-08-17

Deficiency of osteoprotegerin (OPG), a soluble decoy receptor for activator nuclear factor-κB ligand (RANKL), in mice induces osteoporosis caused by enhanced bone resorption. Serum concentrations RANKL are extremely high OPG-deficient (OPG−/−) mice, suggesting that circulating is involved osteoclastogenesis. RANKL−/− exhibit osteopetrosis, with the absence osteoclasts. We examined requirements osteoclastogenesis using OPG−/− and system involving morphogenetic protein 2 (BMP-2)-induced...

10.1210/en.2006-0216 article EN Endocrinology 2006-04-21

To elucidate current epidemiologic, clinical, and immunologic profiles treatments of stiff-person syndrome (SPS) in Japan.

10.1212/nxi.0000000000200165 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2023-09-22

Background/Objectives: This study aimed to evaluate the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with peripheral arterial disease (PAD) undergoing femoral endarterectomy. Methods: We performed a retrospective analysis our institutional data, evaluating consecutive PAD who underwent endarterectomy between January 2013 and March 2023. The main objective was assess NLR for 5-year mortality. Additionally, we examined its relationship perioperative...

10.3390/jcm14010211 article EN Journal of Clinical Medicine 2025-01-02

Background: Drug-coated balloons (DCBs) have been reported to lowered the rate of restenosis and revascularization after endovascular treatment (EVT) femoropopliteal (FP) lesions. Meanwhile, chronic kidney disease requiring hemodialysis (HD), which is becoming more prevalent in Japanese clinical settings, has associated with poorer outcomes EVT for FP This study aimed retrospectively analyze impact HD on using a DCB single center. Methods: included 161 consecutive lesions 127 patients...

10.3390/jcm14051474 article EN Journal of Clinical Medicine 2025-02-22

Abstract Osteoprotegerin (OPG) is a decoy receptor for activator of NF-κB ligand (RANKL). We previously reported that OPG deficiency elevated the circulating level RANKL in mice. Using OPG−/− mice, we investigated whether involved shedding by cells expressing RANKL. Osteoblasts and activated T culture released large amount absence OPG. or soluble form (the RANKL) suppressed release from those cells. OPG- cell-double-deficient mice showed an serum equivalent to indicating mainly derived bone....

10.4049/jimmunol.178.1.192 article EN The Journal of Immunology 2007-01-01

Objectives The aim of this study was to investigate the effect granulocyte-colony stimulating factor (G-CSF) on mesenchymal stem cell (MSC) proliferation in vitro and determine whether pre-microfracture systemic administration G-CSF (a bone marrow stimulant) could improve quality repaired tissue a full-thickness cartilage defect rabbit model. Methods MSCs from rabbits were cultured control medium with (low-dose: 4 μg, high-dose: 40 μg). At one, three, five days after culturing, cells...

10.1302/2046-3758.63.bjr-2016-0083 article EN cc-by-nc-nd Bone and Joint Research 2017-03-01

Red alga dulse possesses a unique xylan, which is composed of linear β-(1→3)/β-(1→4)-xylosyl linkage. We previously prepared characteristic xylooligosaccharide (DX3, (β-(1→3)-xylosyl-xylobiose)) from dulse. In this study, we evaluated the prebiotic effect DX3 on enteric bacterium. Although was utilized by Bacteroides sp. and Bifidobacterium adolescentis, Ksp. grew slowly as compared with β-(1→4)-xylotriose (X3) but B. adolescentis similar to X3. Therefore, aimed find key hydrolysis enzymes...

10.3390/md18030174 article EN cc-by Marine Drugs 2020-03-20

Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumour. The interaction between high-mobility group box 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) important tumour cell growth. Previously, we identified an anticancer candidate, papaverine, that inhibited HMGB1-RAGE interaction.Our study assessed effects papaverine alone or in combination with temozolomide on U87MG T98G human GBM cells using clonogenicity assays, as well a xenograft mouse...

10.21873/anticanres.13889 article EN Anticancer Research 2019-12-01

// Yohei Yamamoto 1 , Ryota Tamura 2 Toshihide Tanaka Kentaro Ohara 3 Yukina Tokuda Keisuke Miyake 4 Jun Takei Yasuharu Akasaki 5 Kazunari Yoshida Yuichi Murayama and Hikaru Sasaki Department of Neurosurgery, Jikei University School Medicine Kashiwa Hospital, Kashiwa-shi, Chiba 277-8567, Japan Keio Medicine, Shinjuku-ku, Tokyo 160-8582, Division Diagnostic Pathology, Kagawa Kita-gun, 761-0793, Minato-ku, 105-8461, Correspondence to: Tanaka, email: ttanaka@jikei.ac.jp Keywords: bevacizumab,...

10.18632/oncotarget.21978 article EN Oncotarget 2017-10-24

The immunosuppressive tumor microenvironment (TME) contributes to the progression and treatment failure. Our previous study demonstrated alterations in TME during bevacizumab (Bev) therapy human glioblastoma (GB) specimens obtained from patients who underwent surgical resection. Continuous Bev administration downregulates expression of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1), suppresses infiltration associated macrophages (TAMs) regulatory T cells (Tregs), increases...

10.21037/atm.2020.03.11 article EN Annals of Translational Medicine 2020-03-01

Distal radial artery aneurysms of the hand are rare. We herein report a rare case aneurysm in anatomical snuff box.A 61-year-old woman presented with chief complaint mass on back her left hand. A radiological examination showed distal aneurysm. The patient underwent successful surgical excision ligation.We discuss etiologies and management box according to published literature.An accurate diagnosis preoperative blood flow evaluation necessary for appropriate aneurysms.

10.1016/j.ijscr.2016.08.015 article EN International Journal of Surgery Case Reports 2016-01-01

Abstract Dendritic cell (DC)-based immunotherapy has been applied to glioblastoma (GBM); however, biomarkers informing response remain poorly understood. We conducted a phase I/IIa clinical trial investigating tumor-fused DC (TFDC) following temozolomide-based chemoradiotherapy in patients with newly diagnosed GBM and determined prognostic factors receiving TFDC immunotherapy. Twenty-eight adult isocitrate dehydrogenase ( IDH) wild-type IDH- WT) were enrolled; 127 vaccine injections (4.5 ±...

10.1007/s00262-023-03482-8 article EN cc-by Cancer Immunology Immunotherapy 2023-06-29
Coming Soon ...